Skip to Content

Daclatasvir use while Breastfeeding

Drugs containing Daclatasvir: Daklinza

Medically reviewed by Drugs.com. Last updated on Jul 13, 2020.

Daclatasvir Levels and Effects while Breastfeeding

Summary of Use during Lactation

Daclatasvir has not been studied in nursing mothers being treated for hepatitis C infection. Because it is 99% bound to maternal plasma proteins, amounts in breastmilk are likely to be very low. If daclatasvir used alone or in combination with sofosbuvir is required by the mother, it is not a reason to discontinue breastfeeding.[1] Some sources recommend against breastfeeding when daclatasvir is used with ribavirin.

Hepatitis C is not transmitted through breastmilk[2][3] and breastmilk has been shown to inactivate hepatitis C virus (HCV).[4][5] However, the Centers for Disease Control recommends that mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding. It is not clear if this warning would apply to mothers who are being treated for hepatitis C.

Infants born to mothers with HCV infection should be tested for HCV infection; because maternal antibody is present for the first 18 months of life and before the infant mounts an immunologic response, nucleic acid testing is recommended.[2][3]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Hepatitis C) Interferon Alfa, Interferon Alfacon-1, Peginterferon Alfa

References

1.
Spera AM, Eldin TK, Tosone G et al. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women? World J Hepatol. 2016;8:557-65. [PMC free article: PMC4840161] [PubMed: 27134703]
2.
Cottrell EB, Chou R, Wasson N et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158:109-13. [PubMed: 23437438]
3.
Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137. [PMC free article: PMC5885289] [PubMed: 26042815]
4.
Pfaender S, Heyden J, Friesland M et al. Inactivation of hepatitis C virus infectivity by human breast milk. J Infect Dis. 2013;208:1943-52. [PubMed: 24068703]
5.
Tovo PA, Calitri C, Scolfaro C et al. Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. World J Gastroenterol. 2016;22:1382-92. [PMC free article: PMC4721973] [PubMed: 26819507]

Substance Identification

Substance Name

Daclatasvir

CAS Registry Number

1009119-64-5

Drug Class

  • Breast Feeding
  • Lactation
  • Antiviral Agents
  • NS5A Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.